Lundin A P, Delano B G, Quinn-Cefaro R
State University of New York, Health Science Center, Brooklyn 11203.
Pharmacotherapy. 1990 Mar-Apr;10(2 ( Pt 2)):22S-26S.
Epoetin alfa (recombinant human erythropoietin) effectively diminishes the anemia associated with end-stage renal disease (ESRD). Although many clinical manifestations of ESRD have been attributed to uremic toxins, the ability of epoetin alfa therapy to improve several of these conditions, such as diminished energy levels, appetite, cold tolerance, sexual function, and cognitive abilities, suggests that anemia may be an important factor in uremia-associated symptoms. Correction of this anemia results in improvements in the patient's quality of life. These improvements can be measured by objective criteria such as exercise tolerance tests, or by subjective standards such as patient response to questionnaires. In studies to date, both subjective and objective data show that epoetin alfa therapy significantly improves the quality of life of patients with ESRD.
促红细胞生成素α（重组人促红细胞生成素）能有效减轻与终末期肾病（ESRD）相关的贫血。尽管ESRD的许多临床表现都归因于尿毒症毒素，但促红细胞生成素α治疗能改善其中一些状况，如精力水平下降、食欲、耐寒能力、性功能和认知能力，这表明贫血可能是尿毒症相关症状的一个重要因素。纠正这种贫血可改善患者的生活质量。这些改善可以通过运动耐量测试等客观标准来衡量，也可以通过患者对问卷的反应等主观标准来衡量。在迄今为止的研究中，主观和客观数据均显示促红细胞生成素α治疗能显著改善ESRD患者的生活质量。
